Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II disitamab vedotin in advanced HER2-positive Paget’s disease
ChiCTR2400088348Phase 2Not yet recruiting
- Sponsor
- Fudan University Shanghai Cancer Center
- Start
- Aug 2024
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of disitamab vedotin in Paget disease of the breast and Paget's disease of bone, sponsored by Fudan University Shanghai Cancer Center. Primary endpoint: Objective response rate. Planned start Aug 2024; status: not yet recruiting.
02
Drugs
disitamab vedotin
03
Conditions
Paget disease of the breastPaget's disease of bone
Beyond the preview
Go deeper on ChiCTR2400088348.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400088348.